Follow Edwards Lifesciences to never miss an important update.
The FDA has approved the AUTUS valve, the first surgical pulmonary valve designed specifically for children with congenital heart disease. Unlike traditional valves, this one is size-adjustable, which helps solve a major problem for pediatric patients who often need multiple surgeries as they grow.
While this is a smaller market than the company's main adult valve business, it is a clear win for its technology. It shows the company can adapt its expertise in heart valves to specialized needs, potentially reducing the number of open-heart surgeries children have to face over their lifetimes.
Source: Business Wire
The Centers for Medicare & Medicaid Services, the federal agency that sets rules for what Medicare will pay for, updated its coverage policy for heart valve replacements performed through a small tube in the leg. This procedure, known as TAVR, is the core of the company's business. The new rules aim to make it easier for more patients to get the treatment while keeping a team of different heart specialists involved in the care.
This is a helpful step for the company because its main business has slowed down recently as the market matures. By making the procedure more accessible to more people, these updated rules could help stabilize growth in its most important product line. It also reinforces the company's position as the leader in this specific type of heart therapy.
Source: Business Wire
Donald E. Bobo, Jr., who serves as Corporate Vice President of Strategy and Corporate Development, has notified the board of his plan to retire by mid-year 2027. The company plans to start looking for a successor immediately to allow for a transition period during 2027. Bobo is also expected to stay on as a consultant through the end of that year.
While Bobo leads the team responsible for long-term planning and acquisitions, this is an orderly departure with a very long lead time. Because the exit is nearly a year away and includes a transition plan, it is a routine leadership change rather than a sudden shift in the company's direction.
Source: 8-K filing
Leerink Partners raised its rating on the company to outperform, which is their way of saying they expect the stock to do better than the rest of the market. The move came after the company reported better-than-expected results for the second quarter.
Analysts are gaining confidence that the core business of replacing aortic valves without surgery is stabilizing. While this market is maturing, the company is managing to grow it at about 10 percent while also launching new products for other heart valves. This suggests the company can maintain its lead even as competition increases.
Source: Leerink Partners
The company reported second-quarter revenue of 1.74 billion dollars, which was higher than the 1.70 billion dollars analysts expected. Earnings per share also came in ahead of targets at 0.78 dollars. The stock rose about 7 percent following the news as the company raised its sales growth forecast for the full year to between 10 and 11 percent.
This is an important result because it shows the core business, which replaces heart valves using a tube instead of open-heart surgery, is still growing at a double-digit pace. Investors have been worried that this market was slowing down, but a 10.5 percent growth rate in that unit suggests there is still plenty of demand. Meanwhile, the newer business focused on repairing different types of heart valves brought in nearly 196 million dollars, showing the company is successfully building a second engine for growth.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Management consistently sets a predictable bar and clears it by a few cents, showing they have a tight grip on their costs and a clear view of their sales.
| Expectation | |
|---|---|
| EPS | $0.74 |
| Revenue | $1.68B |
Follow Edwards Lifesciences to get the latest and most important updates.
Follow EW